What DeepScribe Announced About New York Cancer & Blood Specialists

DeepScribe said on 22 April 2025 that New York Cancer & Blood Specialists had adopted its Ambient Operating System. The announcement describes the practice as one of the leading oncology practices in the country, with more than 30 locations and 35 hospital affiliations, caring for people with cancer and blood disorders in their own communities. Dr Jeff Vacirca, an oncologist and the practice chief executive, and Matthew Ko, the DeepScribe chief executive and co-founder, are both quoted. The announcement gives no figures from the practice itself: no number of clinicians live, no time saved and no note accuracy measure.

Why the DeepScribe Rollout at New York Cancer & Blood Specialists Matters to Community Oncology

The useful fact is the shape of the buyer. More than 30 sites with 35 hospital affiliations means the tool has to work across many different records setups and referral habits, not one tidy building, and that is where ambient documentation usually gets uncomfortable. A chief executive who is also a practising oncologist signing it off is a real signal too, because he has to use the thing he bought. What is not here is any result. An adoption announcement tells you a contract was signed, and that is all it tells you. The figures in the release come from the vendor, so a practice this size reporting its own numbers a year later would be worth far more than the announcement.

Where the DeepScribe Update Comes From

DeepScribe is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

DeepScribe original source.

How We Would Research the DeepScribe Rollout at New York Cancer & Blood Specialists

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would ask New York Cancer & Blood Specialists how many of its 30 or more locations are actually live and how many clinicians use it daily.
  2. Then we would ask what it measured before the rollout, because a practice this size can afford a proper before and after.
  3. We would ask who reviews note accuracy and what happens when a note is wrong, since nobody in the announcement mentions accuracy at all.